Updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women

7487
The new publication reviews and updates the 2013 European guidance for the diagnosis and management of osteoporosis in postmenopausal women and provides a platform on which specific guidelines can be developed at the national level.

The clinical significance of osteoporosis lies in the painful, debilitating fractures that arise, which are a major cause of long-term disability in the population. Nevertheless, osteoporosis is under-diagnosed and undertreated: in the European Union, it is estimated that 57 % of women at high risk of fragility fracture due to osteoporosis do not receive bone-specific treatment. In patients with fragility fractures, less than 20 % receive treatment to reduce the chance of a future fracture.

The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) have published an updated guidance to aid healthcare professionals in diagnosing and managing osteoporosis in postmenopausal women. The present guidance reviews and updates the 2013 guidance in all key areas and includes new information on the evaluation of bone microstructure in fracture risk assessment, the role of FRAX® and Fracture Liaison Services in secondary fracture prevention, long-term effects on fracture risk of dietary intakes, and increased fracture risk on stopping drug treatment.

> Download European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Endorsed by the Scientific Advisory Board of ESCEO as well as the Committees of Scientific Advisors and National Societies of the IOF, the recommendations in this guideline are intended for all healthcare professionals involved in the management of osteoporosis.

This new guidance aims to stimulate a cohesive approach to the management of osteoporosis in Europe by providing an updated platform on which specific guidelines can be developed or revised at a national level,”

explains Professor John Kanis, Honorary President of IOF.

Professor Jean-Yves Reginster, ESCEO President and Chair of the IOF Committee of National Societies, concludes:

Although this guidance has a European perspective and is focussed on postmenopausal women, the recommendations can be of assistance in other regions of the world and in men. The hope is that the recommendations will facilitate improved prevention and management for at-risk individuals and ultimately serve to alleviate the high societal and personal costs posed by osteoporosis to healthcare systems and patients with osteoporosis.”

In addition to the full guidance in Osteoporosis International, executive summaries will be published in the journals Calcified Tissue International and Aging Clinical and Experimental Research.

###

Reference
Kanis JA, Cooper C, Rizzoli R and Reginster JY on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2018). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. https://doi.org/10.1007/s00198-018-4704-5.  https://link.springer.com/article/10.1007%2Fs00198-018-4704-5

About IOF
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as 240 patient, medical and research societies in 99 locations, work together to make fracture prevention and healthy mobility a global health care priority.  http://www.iofbonehealth.org; http://www.facebook.com/@iofbonehealth

About ESCEO
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. www.esceo.org 

Tag: 
Region: